Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Neuroinflammation, Serotonin, Impulsivity and Suicide (NISIS)

30 juni 2016 uppdaterad av: University Hospital, Montpellier

Suicide is a major health problem that causes annually a million death worlwide. In the stress-vulnerability model, suicidal behavior (SB) results from the interaction between an individual's predisposition (personality, family history of SB…) and stressful conditions (early life adversity).

Studies show that suicide ideations could favour inflammation and that depression is associated with an elevated inflammation.

Recent evidences also suggest that inflammatory mediators play a critical role in SB.

The aim of the study is to evaluate the inflammatory markers rate on depressed patients with or without personal history of SB.

In the second part of the study, the relations between the rates of inflammatory markers and characteristics of SB, impulsivity, psychological pain, childhood abuse and gene expression of 5HT2B receptor will be investigated.

Studieöversikt

Status

Okänd

Intervention / Behandling

Detaljerad beskrivning

Over one year, we will recruit 280 patients suffering from a major depressive episode with (n=140) and without any history of suicide attempt (n=140), from a specialized clinic for mood disorders and SB.

First visit : clinical, biological and neuropsychological assessment

Second visit, at 6 month : Follow-up visit in the department or interview by telephone in order to assess suicidal ideations or suicide attempts since the inclusion.

Studietyp

Interventionell

Inskrivning (Förväntat)

280

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Ages of 18 and 65
  • Main diagnosis of major depressive episode (DSM-IV criteria)
  • Having signed the informed consent
  • Able to understand nature, aims, and methodology of the study

Specifics Inclusion criteria:

  • Depressed patients with suicide attempt history :

    • Have done in his lifetime at least one suicide attempt (however the period of time between inclusion and suicide attempt)
  • Depressed patients without suicide attempt history :

    • Had never realized suicide attempt in his lifetime

Exclusion Criteria:

  • Patients suffering from inflammatories pathology
  • Antibiotic or anti-inflammatory current treatment
  • Pregnancy
  • Participation in another clinical trial with an exclusion period
  • Patient on protective measures (guardianship or trusteeship)

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Övrig: Depressive patients
Blood samples (inflammatory biomarkers and genetic purpose) on depressive patients with or without story of suicidal behavior
Blood sample in order to study inflammatory biomarkers and genetics purpose

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Rate of interleukin 2 (Il2) in a blood sample
Tidsram: inclusion visit
Comparison of Il2 levels between patients with and without suicidal behaviour
inclusion visit

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Rate of inflammation markers (Interleukin 1, 4, 6, 8, 10, Tumor necrosis factor alpha (TNF-a), Interferon gamma (IFNg), Vascular endothelial growth factor (VEGF), kynurenin and c-reactive protein (CRP) in a blood sample
Tidsram: inclusion visit
Comparison of the levels of theses markers between patients with and without suicidal behaviour
inclusion visit
Rate of inflammation markers and suicide attempt
Tidsram: inclusion visit
Comparison of rate bloodmarkers inflammation (Il1, 4, 6, 8, 10, TNF-a, IFNg, VEGF, kynurenine and CRP) in depressed patients with latest suicide attempt and depressed patients with an history of suicide attempt
inclusion visit
Rate of inflammation markers and violent suicide attempt
Tidsram: inclusion visit
Comparison of rate bloodmarkers inflammation (Il1, 4, 6, 8, 10, TNF-a, IFNg, VEGF, kynurenine and CRP) in depressed patients with and without violent suicide attempt
inclusion visit
Rate of inflammation markers and suicide ideations
Tidsram: inclusion visit
Comparison of rate bloddmarkers (Il1, 4, 6, 8, 10, TNF-a, IFNg, VEGF, kynurenine and CRP) in depressed patients with and without current suicide ideation
inclusion visit
Relation between markers of inflammation and suicidal behavior characteristics
Tidsram: inclusion visit
Studying relations with bloodmarkers inflammation rate (Il1, 4, 6, 8, 10, TNF-a, IFNg, VEGF, kynurenine and CRP) and suicidal behaviour characteristics (the last and the most serious) (intentionality, planification, lethality)
inclusion visit
Relation between markers of inflammation and impulsivity
Tidsram: inclusion visit
Studying relations with bloodmarkers inflammation rate (Il1, 4, 6, 8, 10, TNF-a, IFNg, VEGF, kynurenine and CRP) and impulsivity (by Baratt Impulsivity Scale and neuropsychological tests)
inclusion visit
Relation between markers of inflammation and psychological pain
Tidsram: inclusion visit
Studying relations with bloodmarkers inflammation rate (Il1, 4, 6, 8, 10, TNF-a, IFNg, VEGF, kynurenine and CRP) and psychological pain (by Likert scale)
inclusion visit
Relation between markers of inflammation and child abuse
Tidsram: inclusion visit
Studying relations with bloodmarkers inflammation rate (Il1, 4, 6, 8, 10, TNF-a, IFNg, VEGF, kynurenine and CRP) and child abuse
inclusion visit
Relation between markers of inflammation and gene expression
Tidsram: inclusion visit
Studying relations with bloodmarkers inflammation rate (Il1, 4, 6, 8, 10, TNF-a, IFNg, VEGF, kynurenine and CRP) and gene expression of 5HT2B receptor
inclusion visit
Markers of inflammation as a risk factor for suicidal behavior
Tidsram: at 6 months
Studying bloodmarkers inflammation rate (Il1, 4, 6, 8, 10, TNF-a, IFNg, VEGF, kynurenine and CRP) as suicidal behaviour risk factor (suicide ideations and/or suicide attempt) with a 6 months follow-up.
at 6 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 november 2015

Primärt slutförande (Förväntat)

1 maj 2017

Avslutad studie (Förväntat)

1 november 2017

Studieregistreringsdatum

Först inskickad

30 juni 2016

Först inskickad som uppfyllde QC-kriterierna

30 juni 2016

Första postat (Uppskatta)

6 juli 2016

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

6 juli 2016

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

30 juni 2016

Senast verifierad

1 juni 2016

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • UF9467
  • 2014-A01313-44 (Annan identifierare: ANSM)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera